Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNTO-3649
- Development stage
- Phase 1
- Lead developer
- Janssen Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
CNTO-3649 is a monoclonal antibody drug candidate developed by Janssen Biotech (a Johnson & Johnson company) and Janssen Pharmaceuticals. It acts as an agonist of the glucagon-like peptide 1 receptor (GLP-1R). The drug was investigated for the treatment of type 2 diabetes mellitus, with studies focusing on its safety, pharmacokinetics, and pharmacodynamics in both healthy adults and patients with type 2 diabetes. Administration routes included intravenous infusion and subcutaneous injection. Clinical development reached Phase 1 trials[1][2][3][4][5][7].
- Other names
- PEGylated FGF21 analogPEGylated recombinant human FGF21
02
Targets
Beyond the preview
Go deeper on CNTO-3649.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNTO-3649.